NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM ® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has completed the first phase of its pharmacokinetic clinical study on its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC). The multi-phase study is aimed to understand how cannabis may serve as a
February 18, 2020
· 3 min read